PMID- 25174729
OWN - NLM
STAT- MEDLINE
DCOM- 20151026
LR  - 20161125
IS  - 1791-2431 (Electronic)
IS  - 1021-335X (Linking)
VI  - 32
IP  - 5
DP  - 2014 Nov
TI  - MicroRNA-145 inhibits cell proliferation by directly targeting ADAM17 in 
      hepatocellular carcinoma.
PG  - 1923-30
LID - 10.3892/or.2014.3424 [doi]
AB  - MicroRNAs (miRNAs) are key regulators in cell processes. Emerging evidence has 
      suggested that there is a direct association between miRNAs and cancer. However, 
      the exact regulatory mechanisms of miRNAs in tumorigenesis are poorly understood. 
      In the present study, we showed that miR-145 is able to significantly reduce mRNA 
      and protein expression levels of A disintegrin and metalloproteinase 17 (ADAM17) 
      in liver cancer cells (SMMC-7721, BEL-7402 and Huh-7). Dual luciferase reporter 
      assays confirmed that ADAM17 is a direct target of miR-145. Notably, we found 
      that miR-145 inhibits cell proliferation and growth activity in SMMC-7721 cells. 
      These results demonstrated that it may be exert the function of tumor suppression 
      in a particular link of cancer cell growth. Further studies revealed that the 
      silencing of ADAM17 decreased the proliferation and growth activity of SMMC-7721 
      cells. Moreover, it reduced the expression of MMP-9. In conclusion, miR-145 
      inhibits liver cancer cell proliferation by directly targeting ADAM17. Thus, it 
      may become a promising biological target in the treatment strategy of 
      hepatocellular carcinoma.
FAU - Liu, Yuwu
AU  - Liu Y
AD  - Department of Pathology, Xiangya Hospital, Central South University, Changsha, 
      Hunan 410008, P.R. China.
FAU - Wu, Chang
AU  - Wu C
AD  - Department of Pathology, Shenzhen Sixth People's Hospital (Nanshan Hospital), 
      Shenzhen, Guangdong 518052, P.R. China.
FAU - Wang, Ying
AU  - Wang Y
AD  - Department of Pathology, Xiangya Hospital, Central South University, Changsha, 
      Hunan 410008, P.R. China.
FAU - Wen, Sailan
AU  - Wen S
AD  - Department of Pathology, Xiangya Hospital, Central South University, Changsha, 
      Hunan 410008, P.R. China.
FAU - Wang, Junpu
AU  - Wang J
AD  - Department of Pathology, Xiangya Hospital, Central South University, Changsha, 
      Hunan 410008, P.R. China.
FAU - Chen, Zhihong
AU  - Chen Z
AD  - Department of Pathology, Xiangya Hospital, Central South University, Changsha, 
      Hunan 410008, P.R. China.
FAU - He, Qiongqiong
AU  - He Q
AD  - Department of Pathology, Xiangya Hospital, Central South University, Changsha, 
      Hunan 410008, P.R. China.
FAU - Feng, Deyun
AU  - Feng D
AD  - Department of Pathology, Xiangya Hospital, Central South University, Changsha, 
      Hunan 410008, P.R. China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140820
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (MIRN145 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - EC 3.4.24.- (ADAM Proteins)
RN  - EC 3.4.24.35 (MMP9 protein, human)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
RN  - EC 3.4.24.86 (ADAM17 Protein)
RN  - EC 3.4.24.86 (ADAM17 protein, human)
SB  - IM
MH  - ADAM Proteins/*antagonists & inhibitors/genetics
MH  - ADAM17 Protein
MH  - Carcinoma, Hepatocellular/genetics/metabolism/*pathology
MH  - Cell Cycle
MH  - Cell Line, Tumor
MH  - Cell Movement
MH  - Cell Proliferation
MH  - HEK293 Cells
MH  - Humans
MH  - Liver Neoplasms/genetics/metabolism/*pathology
MH  - Matrix Metalloproteinase 9/metabolism
MH  - MicroRNAs/genetics/*metabolism
EDAT- 2014/09/02 06:00
MHDA- 2015/10/27 06:00
CRDT- 2014/09/02 06:00
PHST- 2014/04/13 00:00 [received]
PHST- 2014/07/25 00:00 [accepted]
PHST- 2014/09/02 06:00 [entrez]
PHST- 2014/09/02 06:00 [pubmed]
PHST- 2015/10/27 06:00 [medline]
AID - 10.3892/or.2014.3424 [doi]
PST - ppublish
SO  - Oncol Rep. 2014 Nov;32(5):1923-30. doi: 10.3892/or.2014.3424. Epub 2014 Aug 20.